Introduction
Highly active antiretroviral therapy, involving the co-administration of nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and/or protease inhibitors, is a standard treatment regimen for human immunodeficiency virus (HIV) infections. This regimen suppresses the replication of HIV and controls disease progression in HIV-infected patients. 1, 2 Unfortunately, however, an increasing number of patients with HIV infection/AIDS have failed to respond to the current antiretroviral therapeutics because of serious problems including the emergence of drug-resistant HIV variants 3 and drug-related adverse effects. 4 With this in mind, there is therefore a continuous need to develop novel anti-HIV drugs that are more effective against drug-resistant viruses and produce fewer adverse effects. Recently, a series of extensive studies led to the development of a series of novel antiretrovirals with new mechanisms of action for anti-HIV therapy, including a fusion inhibitor (enfuvirtide), [5] [6] [7] an integrase inhibitor (raltegravir), 8, 9 and a CC chemokine receptor type 5 (CCR5) antagonist (maraviroc). 10, 11 CXC chemokine receptor type 4 (CXCR4) antagonists, [12] [13] [14] [15] [16] CD4 mimics, [17] [18] [19] [20] gp41-binding peptides [21] [22] [23] and small molecules [24] [25] [26] represent promising alternative anti-HIV agents.
3,4-Dihydro-2H,6H-pyrimido[1,2-c] [1, 3] benzothiazin-6-imine (PD 404182) (1) was previously reported as an antimicrobial agent that inhibited 3-deoxy-D-manno-octulosonic acid 8-phosphate synthase 27 and phosphopantetheinyl transferase ( Figure 1 ). 28, 29 Following a recent random screening program using a multinuclear activation of a galactosidase indicator (MAGI) assay, compound 1 was identified as a new antiretroviral candidate with a high therapeutic index (CC 50 /EC 50 > 200).
The MAGI assay allows for the inhibitory activity of an early-stage HIV infection, including inhibition of the virus attachment and membrane fusion to host cells, to be effectively evaluated. 30 Compound 1 showed a similar antiviral profile in HIV-1 infection to DS 5000 31 (adsorption inhibitor) and enfuvirtide (fusion inhibitor). The virucidal effects of compound 1 against the human hepatitis C virus, HIV, and simian immunodeficiency virus have also been reported. 32, 33 The mechanism of action for compound 1, however, has not yet been fully understood.
In our previous structure-activity relationship (SAR) study of compound 1, 34 a number of PD 404182 derivatives were designed and synthesized according to a series of facile synthetic procedures, 35, 36 in which the tricyclic heterocycles related to PD 404182 were easily obtained in a few steps from benzaldehydes via C-H functionalization or aromatic nucleophilic substitution. The 6-6-6 fused pyrimido[1,2-c] [1, 3] benzothiazine scaffold and the heteroatom arrangement in the 1,3-thiazin-2-imine moiety are indispensable for the inhibitory activity of compound 1 against HIV infection ( Figure 1 ). Optimization studies indicated that the introduction of a hydrophobic group on the benzene ring and the cyclic amidine substructures effectively improved the antiviral activity by generating a potentially favorable interaction(s) with the target molecule(s). The most potent compounds identified were 2-fold more potent than PD 404182 and contained a phenyl group at 9-position of pyrimido[1,2-c] [1, 3] benzothiazine (compound 2) or a geminal dimethyl group on the pyrimidine moiety (compound 3) (Figure 2 ).
In the current study, further structural optimization was conducted from the lead compounds 2 and 3 according to three approaches (Figure 2 ), including the introduction of substituents on the 9-phenyl group (I), the substitution of the 9-phenyl group with fused arenes or heterocycles (II), and the modification of the cyclic amidine moiety (III). The anti-HIV profiles of the most potent derivative are also described.
Results and discussion

Synthesis of 9-aryl-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives.
The 9-Aryl-3,4-dihydro-2H,6H-pyrimido[1,2-c] [1, 3] benzothiazin-6-imine derivatives (7 and 8)
were synthesized using a Suzuki-Miyaura cross-coupling reaction [37] [38] [39] of N-(tert-butyl)-protected bromide 4 with aryl boronic acid (pinacol ester) or by an Ullmann coupling 40 with pyrazole or imidazole (Scheme 1). Subsequent trifluoroacetic acid (TFA)-mediated deprotection of the tert-butyl groups afforded the desired biaryl-type derivatives.
Synthesis of spiropyrimidine-fused benzothiazinimine derivatives.
The synthesis of the spiropyrimidine-fused derivatives started with the dialkylation of malononitrile with dihaloalkanes (9, 10, or 12, Scheme 2). BH 3 -mediated reduction of the alkylated malononitriles (13-15) followed by oxidative amidination 41 with 4-bromo-2-fluorobenzaldehyde gave the 2-phenyl-1,4,5,6-tetrahydropyrimidine derivatives (16) (17) (18) We initially examined substituent effects at the para-position of the 9-phenyl group of compound 2 ( Table 1 Similar anti-HIV activities to that of compound 2 were also exhibited by the ortho-methoxy (7s)
and ortho-phenyl (7t) derivatives (EC 50 = 0.41 and 0.32 M, respectively), suggesting that the twisted conformation of the biaryl axis in the 9-aryl-modified PD 404182 derivatives can be tolerated and can interact with the target molecule(s).
To develop more potent anti-HIV agents, several compounds were designed with bis-and tris-modifications on the 9-phenyl group of compound 2 ( Table 1 The substitution of the 9-phenyl group with a variety of different heterocyclic substructures was also investigated (Table 2 ). Pyridine substitution (8h and 8i) led to a slight reduction in the anti-HIV activity (EC 50 = 0.45 and 0.54 M, respectively), whereas the introduction of a furan (8j), benzofuran (8k), thiophene (8l), benzothiophene (8m), and pyrazole (8n) was well tolerated and had little impact on the activity relative to compound 2 (EC 50 = 0.20-0.42 M). It is worthy of note that the substitution of the 9-phenyl group with a basic imidazole moiety led to a significant reduction in the anti-HIV (8o, EC 50 = 5.12 M).
Taken together, these data led to the identification of two highly potent compounds 7p and 8c
respectively. Furthermore, no cytotoxic effects were observed for these derivatives at 10 M in the MAGI assay.
Structure-activity relationships of spiropyrimidine-fused benzothiazinimine derivatives.
Several spiropyrimidine-fused derivatives were designed for the SAR study based on the geminal dimethylpyrimidine substructure 3 (Table 3 ) 42 . Cyclohexane (20) and N-methoxycarbonylpiperidine (24b) derivatives exhibited the similar levels of anti-HIV activity to that of the parent dimethyl derivative 3. In contrast, the tetrahydropyran (22) and N-(p-methoxybenzyl)piperidine (24a) derivatives exerted inhibitory activities that were 5-7-fold lower than that of the parent dimethyl
, and N-carbamoyl-(24e) piperidine derivatives also provided reduced levels of antiviral activity. With this in mind, the N-alkoxycarbonyl piperidine group was identified as a linkage for the introduction of additional functional group(s) to PD 404182 with potent anti-HIV activity (24b).
Anti-HIV profiles of the most potent derivative 8c.
A time-of-drug addition study was carried out to further investigate the anti-HIV profile of the most potent derivative 8c as an anti-HIV agent ( Figure 3 ). This assay has been used previously to approximately determine which stage in the replication cycle of HIV-1 is inhibited by the compound. Two compounds (1 and 8c) were selected for testing in this assay together with five standard anti-HIV agents, including DS5000 (adsorption inhibitor), 31 enfuvirtide (fusion inhibitor), 6, 7 AZT (NRTI), 43 nevirapine (NNRTI), 44, 45 and raltegravir (integrase inhibitor). 8, 9 The results revealed that the infection profile in the presence of compound 8c was similar to that of DS5000 and enfuvirtide, suggesting that 8c exerted its anti-HIV activity at the early stages of the viral infection, including the binding and fusion stage. This was similar to PD 404182, indicating that the bioactivity profile was not influenced by the newly appended functional group(s).
We also evaluated the antiviral activity of compounds 1 and 8c against several HIV strains such as HIV-1 NL4-3 , HIV-1 BaL , HIV-2 EHO , and HIV-2 ROD . This study enabled us to estimate the impact of the target molecules on the process of binding and fusion because these viruses have different susceptibilities 46 to different anti-HIV agents. These results implied that compounds 1 and 8c
exhibited their anti-HIV activity through different mechanisms from those of the known binding and fusion inhibitors including CCR5 antagonists, CXCR4 antagonists, and enfuvirtide. In addition, compound 8c was 2-3-fold more effective against these HIV-1 and HIV-2 strains than PD 404182 (Table 4) .
Conclusions
In conclusion, we have designed and synthesized a series of PD 404182 derivatives for the Shimadzu LC-10ADvp (Shimadzu Corp., Ltd., Kyoto, Japan), and eluting products were detected by UV at 254 nm. The purity of the compounds was determined by combustion analysis or HPLC analysis as >95%.
General procedure of Suzuki-Miyaura cross coupling for 9-aryl pyrimido[1,2-c][1,3]-thiazine derivatives 5 and 6: N-(tert-butyl)-3,4-dihydro-9-(4-methoxycarbonylphenyl)-2H,6H-
pyrimido[1,2-c][1,3]benzothiazin-6-imine 5a.
To a solution of bromide 4 (52.8 mg, 0.15 mmol) and 4-(methoxycarbonyl)phenylboronic acid (32.4 mg, 0.18 mmol) in a mixture of toluene (1.5 mL), EtOH (0.9 mL) and 1 M aq. K 2 CO 3 (1.5 mL) was added Pd(PPh 3 ) 4 (6.9 mg, 4 mol%) and PdCl 2 (dppf)·CH 2 Cl 2 (3.7 mg, 3 mol%). After being stirred under reflux for 1 h, the mixture was extracted with CHCl 3 . The organic layers were dried over MgSO 4 and concentrated. The residue was purified by flash chromatography over aluminum oxide with n-hexane-EtOAc (10:0 to 9:1) to give the compound 5a as colorless solid 
N-(tert-Butyl)-3,4-dihydro-9-(1H-pyrazol-1-yl)-2H,6H-pyrimido[1,2-c][1,3]benzo-
thiazin-6-imine (6n).
To 
Bis(2-chloroethyl)-N-(4-methoxybenzyl)amine (12).
To a suspension of bis(2-chloroethyl)amine hydrochloride 11 (8.92 g, 50.0 mmol) in CH 2 Cl 2 (300 mL) were added Et 3 N (2.89 mL, 100.0 mmol) and 4-methoxybenzoyl chloride (6.77 mL, 50.0 mmol). After being stirred at rt for 2 h, the reaction mixture was washed with 1N HCl, sat. NaHCO 3 , brine, and dried over MgSO 4 . After concentration, the residue was dissolved in anhydrous Et 2 O (250 mL) and LiAlH 4 (2.1 g, 55.0 mmol) was slowly added at 0 °C under an Ar atmosphere. After being stirred at rt overnight, the reaction mixture was quenched by addition of water, 2N NaOH, and water. The mixture was dried over MgSO 4 . After concentration, the residue was purified by flash chromatography over silica gel with n-hexane-EtOAc 
1-(4-Methoxybenzyl)piperidine-4,4-dicarbonitrile (15).
To a solution of malononitrile (2.49 g, 37.7 mmol) in DMF (94.3 mL) was added K 2 CO 3 (5.73 mg, 41.5 mmol). After being stirred at 65 °C for 2 h, a solution of chloride 12 (9.88 mg, 37.7 mmol)
in DMF (37.7 mL) was added. After being stirred at same temperature for 5 h, EtOAc was added.
The mixture was washed with 5% aq. NaHCO 3 , and dried over MgSO 4 . After concentration, the residue was purified by flash chromatography over silica gel with n-hexane-EtOAc 
3-(4-Bromo-2-fluorophenyl)-9-(4-methoxybenzyl)-2,4,9-triazaspiro[5.5]undec-2-ene (18).
To a solution of nitrile 15 (4.05 g, 15.9 mmol) in THF (39.8 mL) was added BH 3 in THF (79.5 mL, 79.5 mmol, 1.0 M) at 0 °C under an Ar atmosphere. The mixture was warmed to rt. After being stirred at 65 °C for 5 h, the reaction mixture was cooled to 0 °C, and 1N HCl was added. After being stirred at rt for 1 h, the mixture was basified with 2N NaOH. The whole was extracted with 
Determination of anti-HIV activity.
The sensitivity of three HIV-1 strains and two HIV-2 strains was determined by the MAGI assay. 
